Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,729 INR | -0.55% | -1.86% | -10.11% |
04-08 | Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals | CI |
04-08 | Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection | MT |
Sales 2024 * | 56.49B 678M 54.24B | Sales 2025 * | 63.2B 758M 60.68B | Capitalization | 285B 3.41B 273B |
---|---|---|---|---|---|
Net income 2024 * | 8.48B 102M 8.14B | Net income 2025 * | 11.02B 132M 10.58B | EV / Sales 2024 * | 4.55 x |
Net cash position 2024 * | 27.5B 330M 26.4B | Net cash position 2025 * | 31.55B 378M 30.29B | EV / Sales 2025 * | 4.01 x |
P/E ratio 2024 * |
33.5
x | P/E ratio 2025 * |
25.8
x | Employees | 4,585 |
Yield 2024 * |
0.1% | Yield 2025 * |
0.2% | Free-Float | 38.38% |
Latest transcript on Gland Pharma Limited
1 day | -0.55% | ||
1 week | -1.86% | ||
Current month | -6.13% | ||
1 month | -3.28% | ||
3 months | -8.90% | ||
6 months | +12.75% | ||
Current year | -10.11% |
Managers | Title | Age | Since |
---|---|---|---|
Srinivas Sadu
CEO | Chief Executive Officer | 55 | 31/12/99 |
Director of Finance/CFO | - | 29/09/19 | |
C. S. Venkatesan
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/97 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fang Yao
BRD | Director/Board Member | 54 | 09/03/22 |
Srinivas Sadu
CEO | Chief Executive Officer | 55 | 31/12/99 |
Yiu Kwan Lau
CHM | Chairman | 69 | 09/06/19 |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 1,729 | -0.55% | 16,516 |
25/04/24 | 1,739 | -1.07% | 7,750 |
24/04/24 | 1,757 | -1.36% | 1,992 |
23/04/24 | 1,782 | +0.26% | 10,473 |
22/04/24 | 1,777 | +0.87% | 2,559 |
Delayed Quote Bombay S.E., April 26, 2024 at 11:00 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- GLAND Stock
- GLAND Stock